Seeking Alpha

Amarin (AMRN +5%) trades up after being awarded a patent for its fish oil pill Vascepa....

Amarin (AMRN +5%) trades up after being awarded a patent for its fish oil pill Vascepa. Citigroup plays catch-up with the rest of the Street by initiating the shares with a Buy and a $20 price target on the news. Citi says that concerns over an exclusivity decision on the pill had put pressure on the stock and driven valuations near a "worst case" scenario, but that overhang has now been removed and the risk/reward is favorable. The firm adds that Vascepa has a near $1B commercial potential, even if AMRN has to launch the drug alone.
Comments (5)
  • At last common sense is prevailing. This is a super company with excellent long term prospects. Hope to hold the stock for the long term. I'm sure it will be profitable!
    27 Nov 2012, 11:47 AM Reply Like
  • Jamil Fadel pharmacist Lebanon target AMRN 27 USD
    27 Nov 2012, 01:06 PM Reply Like
  • Without the NCE , AMRN will not be the block buster we are all hoping for. No Buy Out without NCE and having to do it on its own money will keep this stock from achieving its true potential. Sure hope they get
    NCE in the next Orange Book meeting in December ! If they do, then they will be super attractive as a buyout candidate !!!
    27 Nov 2012, 02:10 PM Reply Like
  • You, Sir, are an idiot!
    27 Nov 2012, 02:53 PM Reply Like
  • I am not sure he is an idiot, but there is fear here that if it doesn't get NCE it will be a long ride for investors. Consider the best scenario, get NCE, offer 25 to 30 done. Take the money and run, if they hire their own sales force it will take years to get cash but perhaps we will get more.
    27 Nov 2012, 05:49 PM Reply Like
DJIA (DIA) S&P 500 (SPY)